2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

602. Myeloid Oncogenesis: Basic: Poster III

Program: Poster Abstract Session
Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Omics Technologies, Bioinformatics, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Non-Biological Therapies, Chemotherapy, Biological Processes, Apoptosis, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Metabolic Disorders, Research, Fundamental Science, AML, Translational Research, CML, Study Population, Human, Animal Model
PAPER

4960 The role and mechanism of targeting MAPKAPK2 in regulating PTPN22 to remodel IL-1β⁺ lams in acute myeloid leukemia

Lihua Wu, Xiaofan Li Sr, MD, PhD2, Nainong Li, MD3
1 Fujian Medical University Union Hospital, Fuzhou, China
2 Fujian Medical University Union Hospital, Fuzhou, China
3 Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union Hospital, Fuzhou, China

Objective: Acute myeloid leukemia (AML) is a highly heterogeneous hematologic malignancy. Its progression is governed by both intrinsic genetic mutations in leukemic cells and abnormal remodeling of the bone marrow microenvironment (BMME). Leukemia-associated macrophages (LAMs) serve as central drivers of immunosuppression and inflammatory responses in AML, yet the core molecular mediators and signaling pathways responsible for their pro-leukemic functions remain poorly clarified. MAPKAPK2 (MK2), a key downstream kinase of the p38 MAPK cascade, mediates inflammatory stress responses; however, its function and detailed mechanism within the AML immune microenvironment have not been systematically investigated. This study integrated genetic causal inference, multi-omics bioinformatics analyses, cellular functional assays and mechanistic validation to elaborate how MK2 remodels IL-1β? LAMs and accelerates AML progression via the MK2/PTPN22–PI3K–AKT–mTOR signaling axis.

Methods: Mendelian randomization (MR) paired with sensitivity analyses using public genetic datasets confirmed the causal link between MK2 and AML onset and progression. Integrated TCGA-GTEx transcriptomic data were compared to assess MK2 expression differences between AML patients and healthy people, as well as its prognostic value. GEO single-cell RNA-seq data were processed routinely to map cell-specific MK2 distribution in marrow immune cells, focusing on MK2 enrichment in M2-like macrophages. Pathway enrichment and immune correlation analyses defined MK2-associated metabolic and immune pathways and built an MK2-centered immune regulatory network. We generated bone marrow-derived macrophage (BMDM) models with MK2 knockdown or overexpression. A C1498 AML cell-BMDM co-culture system and mouse AML models were used to test how MK2-altered macrophages regulate leukemic cell behaviors. CCK-8 and flow cytometry measured AML cell proliferation and apoptosis; flow cytometry also detected macrophage immunosuppressive polarization. Co-IP validated MK2-PTPN22 binding, and western blot assessed PI3K-AKT-mTOR phosphorylation and IL-1β levels. PTPN22 rescue assays under MK2 overexpression verified the essential role of this signaling cascade across molecular, cellular and functional levels.

Results: MR analyses confirmed MK2 causally promotes AML development (P < 0.05 for discovery and validation cohorts). MK2 was markedly overexpressed in AML tissues (P < 0.01), and high MK2 correlated with poor survival (HR = 1.85, 95% CI: 1.21–2.84, P < 0.01), supporting its utility as a prognostic biomarker. Single-cell results showed MK2 mainly localized to marrow macrophages, especially immunosuppressive M2 subsets, and positively correlated with monocyte (R = 0.350, P < 0.001) and M2 macrophage infiltration (R = 0.220, P < 0.01). MK2 upregulation polarized BMDMs toward a pro-tumor phenotype and induced IL-1β? LAM formation. In vitro co-culture and in vivo mouse experiments proved MK2-overexpressing macrophages boost C1498 proliferation and inhibit apoptosis. Mechanistically, MK2 directly binds PTPN22 without changing total PTPN22 protein abundance but suppresses its enzymatic activity, triggering sustained PI3K-AKT-mTOR activation and elevated IL-1β secretion. Restoring PTPN22 reversed pathway overactivation, lowered IL-1β, abolished macrophage pro-tumor features, and eliminated MK2-mediated AML progression. We summarized the complete cascade: MK2 binds and inactivates PTPN22, activates PI3K-AKT-mTOR signaling, remodels IL-1β? LAMs, and drives AML advancement.

Conclusions: Combining causal genetic analysis, multi-omics data, and in vitro/in vivo functional experiments, this study delineates the oncogenic role of MK2 in the AML bone marrow immune microenvironment. We uncovered a novel pathway: MK2 inhibits PTPN22 to maintain PI3K-AKT-mTOR activation, which reprograms pro-leukemic IL-1β? LAMs and accelerates AML progression. Our work offers novel mechanistic insights for microenvironment-targeted treatment and nominates MK2 as a potential therapeutic target for AML.

Lihua Wu: No relevant conflicts of interest to declare.